[A18-11] Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2018
Project no.:
A18-11
Commission:
Commission awarded on 15.02.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Add-on maintenance treatment in adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta agonists
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-42 | Benralizumab (asthma) - Addendum to Commission A18-11 | Commission completed |
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.